Attention: You are using an outdated browser, device or you do not have the latest version of JavaScript downloaded and so this website may not work as expected. Please download the latest software or switch device to avoid further issues.

News > Community news > Crick spinout to begin first-in-human clinical study for leukaemia

Crick spinout to begin first-in-human clinical study for leukaemia

GammaDelta Therapeutics has received Investigational New Drug approval from the US FDA for their GDX012 cell therapy to be investigated as a treatment for blood cancers. 
7 Jun 2021
United States of America
Community news

Featured

Clinicians

To read this story

Similar stories

Last week was Mentoring Week at the Crick, when we celebrate all the different ways that good mentorship supports us. We spoke to some CrickConnect members to find out how mentorin… More...

When Sonia Lalani wanted to take the next step in her career, she started working with a mentor to help figure out what … More...

Over Mentoring Week at the Crick, we spoke colleagues who have benefitted from mentoring in some way. Today, we hear fro… More...

Last month we celebrated Catherine Heffner from the Carlton Lab, who was runner up in the 2021 MRC Max Perutz Science Wr… More...

Feeling comfortable at work is something that many of us take for granted, but for those with a disability, navigating t… More...

Have your say

 
This website is powered by
ToucanTech